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Abstract
Soft tissue sarcoma (STS) is a rare cancer that develops from soft tissues in any part of the
body. Despite major advances in the treatment of STS, patients are often refractory to con-
ventional radiotherapy, leading to poor prognosis. Enhancement of sensitivity to radiother-
apy would therefore improve the clinical outcome of STS patients. We previously revealed
that the tumor-specific, replication-competent oncolytic adenovirus OBP-301 kills human
sarcoma cells. In this study, we investigated the radiosensitizing effect of OBP-301 in
human STS cells. The in vitro antitumor effect of OBP-301 and ionizing radiation in mono-
therapy or combination therapy was assessed using highly radiosensitive (RD-ES and SK-
ES-1) and moderately radiosensitive (HT1080 and NMS-2) STS cell lines. The expression
of markers for apoptosis and DNA damage were evaluated in STS cells after treatment. The
therapeutic potential of combination therapy was further analyzed using SK-ES-1 and
HT1080 cells in subcutaneous xenograft tumor models. The combination of OBP-301 and
ionizing radiation showed a synergistic antitumor effect in all human STS cell lines tested,
including those that show different radiosensitivity. OBP-301 was found to enhance irradia-
tion-induced apoptosis and DNA damage via suppression of anti-apoptotic myeloid cell leu-
kemia 1 (MCL1), which was expressed at higher levels in moderately radiosensitive cell
lines. The combination of OBP-301 and ionizing radiation showed a more profound antitu-
mor effect compared to monotherapy in SK-ES-1 (highly radiosensitive) and HT1080 (mod-
erately radiosensitive) subcutaneous xenograft tumors. OBP-301 is a promising antitumor
reagent to improve the therapeutic potential of radiotherapy by increasing radiation-induced
apoptosis in STS.
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Introduction
Soft tissue sarcoma (STS) is a rare cancer that develops from the soft tissues of any part of the
body. Sarcoma is the third most common cancer in children, accounting for 15.4% of malig-
nant tumors of childhood, and 13,170 new cases of osteosarcoma and STS are diagnosed in the
United States annually [1]. Treatment for STS requires a multidisciplinary approach that
involves surgery, radiotherapy, and chemotherapy [2], with the standard approach for local-
ized STS focusing on surgery and radiotherapy. Despite major advances in the treatment of
STS however, poor response to radiotherapy is a critical prognostic factor, and radiotherapy-
refractory patients often show tumor recurrence, distant metastasis and poor prognosis [3,4].
Therefore, the enhancement of sensitivity to radiotherapy is a critical aspect of improving the
clinical outcome of STS patients.
Radiotherapy is used in STS patients for the local control of residual tumors after surgical
resection [5]. However numerous complications, including fractures, fibrosis, edema, and con-
tractures, hamper the efficacy of this approach. In addition, radiotherapy has the potential to
cause secondary cancers in irradiated tissues [6]. Therefore, radiosensitizing approaches are
required to reduce the dosage of ionizing radiation delivered to STS patients, especially in cer-
tain histological subtypes where the response to radiotherapy is known to be limited [7]. STS
can be divided into distinct histological subtypes, including fibrosarcoma, leiomyosarcoma,
rhabdomyosarcoma, Ewing sarcoma, myxosarcoma, peripheral nerve sheath tumor and peri-
vascular wall tumor [8]. Ewing sarcoma is relatively sensitive to radiotherapy compared to
other STS tumors, however, the precise mechanism determining sensitivity or resistance to
radiotherapy in this disease remains unknown.
Although sensitivity to radiotherapy varies between the histological subtypes of STS, the
underlying mechanism has not been clearly understood. Exposure of cells to ionizing radiation
leads to a number of types of DNA damage, including DNA double-stranded breaks, which
can be detected by the accumulation of γH2AX protein [9]. The expression level of γH2AX
(H2AX phosphorylated at Ser139), is a strong biomarker of double-stranded DNA damage
caused by ionizing radiation [9]. After its initial induction in irradiated tumor cells, the expres-
sion of γH2AX is gradually reduced by the activation of DNA damage repair [10]. In contrast,
tumor cells possess an anti-apoptotic member of the B-cell lymphoma 2 (BCL2) family pro-
teins, including BCL2, myeloid cell leukemia 1 (MCL1), and B-cell lymphoma-extra large
(BCL-xL), to reduce radiation-induced apoptosis. Among the BCL2 family proteins, MCL1 is
frequently overexpressed in various types of malignant tumor, including sarcoma [11]. There-
fore, DNA damage repair and anti-apoptotic function may be involved in the radiosensitivity
of STS.
As a novel therapeutic strategy for treating malignant tumors, we previously generated a tel-
omerase-specific, replication-competent oncolytic adenovirus, OBP-301 (Telomelysin), in
which the human telomerase reverse transcriptase (hTERT) promoter drives the expression of
adenoviral E1A and E1B genes [12]. We confirmed the antitumor effect of monotherapy OBP-
301 in epithelial and mesenchymal types of malignant tumor cells, including osteosarcoma
and STS [12–14], as well as its use in combination with radiation [15] or chemotherapy [16–
18]. A phase 1 clinical study of OBP-301 was conducted in the United States, with the safety of
intratumoral injection of OBP-301 demonstrated in patients with a variety of advanced solid
tumors, including sarcoma [19]. In combination with chemotherapy, we have shown that
OBP-301 adenoviral E1A suppresses the expression of anti-apoptotic MCL1 protein, resulting
in the enhancement of apoptosis induced by cisplatin and doxorubicin [17] or zoledronic acid
[18]. Furthermore, in combination with radiotherapy, OBP-301 adenoviral E1B inhibits the
repair machinery for DNA double strand breaks, enhancing radiation-induced apoptosis [15].
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However, whether OBP-301 can enhance the sensitivity to radiotherapy in STS remains
unclear.
In the present study, we investigated the radiosensitizing effect of OBP-301 in human STS
cell lines. The in vitro efficacy of combined OBP-301 and ionizing radiation was assessed
based on cell viability, apoptosis induction, and DNA damage status. In addition, we assessed
the in vivo antitumor effect of the combination of OBP-301 and ionizing radiation using sub-




We used four human STS cell lines, RD-ES (Ewing sarcoma), SK-ES-1 (Ewing sarcoma),
HT1080 (fibrosarcoma), and NMS-2 (malignant peripheral nerve sheath tumor, MPNST)
[20]. RD-ES, SK-ES-1, and HT1080 cells were obtained from the American Type Culture Col-
lection (ATCC, Manassas, VA, USA). NMS-2 cells were kindly provided by Dr. Hiroyuki
Kawashima (Niigata University, Niigata, Japan). Cells were not cultured for more than 5
months following thawing. The authentification was not performed by the authors. RD-ES
and NMS-2 were grown in RPMI-1640 medium; SK-ES-1 cells were grown in McCoy’s 5a
medium; HT1080 cells were grown in Eagle’s Minimum Essential Medium. All media were
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomy-
cin. The cells were maintained at 37˚C in a humidified atmosphere with 5% CO2.
Recombinant adenovirus
The recombinant telomerase-specific replication-competent adenovirus OBP-301 (Telomely-
sin), in which the hTERT promoter element drives the expression of the adenoviral E1A and
E1B genes linked by an internal ribosome entry site, was previously constructed and character-
ized [12–14]. The particle and infectious titers of OBP-301 were 1 × 1012 viral particles (VP)/
mL and 1 × 1011 plaque-forming units (PFU)/mL, respectively. The VP/PFU ratio of OBP-301
was 10.
Cell viability assay
RD-ES and SK-ES-1 cells were seeded at a density of 3 × 103 cells/well, and HT1080 and NMS-
2 cells were seeded at a density of 1 × 103 cells/well on 96-well plates, 24 h before irradiation or
OBP-301 infection. In monotherapy, cells were irradiated at dosages of 0, 1, 2, 5, or 10 Gy
using an MBR-1520R irradiator (Hitachi Medical Co., Tokyo, Japan). In combination therapy,
cells were infected with OBP-301 at multiplicity of infections (MOIs) of 0, 1, 5, 10, or 50 PFU/
cell. Twenty-four hours after infection, cells were irradiated at dosages of 0, 1, 2, 5, or 10 Gy.
Cell viability was determined on day 4 after irradiation using a Cell Proliferation Kit II (Roche
Molecular Biochemicals Indianapolis, IN, USA) according to the manufacturer’s protocol. The
combined effect of OBP-301 and ionizing radiation was analyzed by calculating the combina-
tion index using the CalcuSyn software (BioSoft, Inc., Cambridge, UK). The computation of
the combination index was based on the method of Chou [21].
Western blot analysis
SK-ES-1 and HT1080 cells (1 × 105 cells), seeded in a 100-mm dish, were prepared for protein
extraction. Cells were treated with OBP-301 at the indicated MOIs for 48 h and/or were irradi-
ated at the indicated dosages 24 h after infection. Cells were transfected with 10 nM MCL1
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small interfering RNA (siRNA), or control siRNA (Applied Biosystems, Foster City, CA, USA)
using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) for 48 h and/or irradiated at
the indicated dosages. Twenty-four hours after irradiation, whole cell lysates were prepared in
a lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100) containing a prote-
ase inhibitor cocktail (Complete Mini; Roche Applied Science, Mannheim, Germany). To fur-
ther assess DNA damage, SK-ES-1 cells (1 × 105 cells), seeded in a 100-mm dish, were infected
with OBP-301 (10 MOI) and then irradiated at 1 Gy, 24 h after infection. Cells were harvested
0.5, 1, and 3 h after irradiation, and whole cell lysates were analyzed by Western blot for
γH2AX expression.
Proteins (20 μg per lane) were separated on 8–15% sodium dodecyl sulfate polyacrylamide
gels and transferred to polyvinylidene difluoride membranes (Hybond-P; GE Healthcare,
Buckinghamshire, UK). Blots were blocked with Blocking-One (Nacalai Tesque, Kyoto, Japan)
at room temperature for 30 min. The primary antibodies used were: mouse anti-Ad5 E1A
monoclonal antibody (mAb) (554155; BD Bioscience, Franklin Lakes, NJ, USA); mouse anti-
γH2AX mAb (05–636; Merck Millipore, Billerica, Massachusetts, USA); rabbit anti-poly
(ADP-ribose) polymerase (PARP) polyclonal antibody (pAb) (9542), rabbit anti-MCL-1 mAb
(39224), and rabbit anti-E2F1 mAb (3742; Cell Signaling Technology, Danvers, MA, USA);
and mouse anti-β-actin mAb (A5441; Sigma-Aldrich, St. Louis, MO, USA). The secondary
antibodies used were: horseradish peroxidase-conjugated antibodies against rabbit IgG
(NA934; GE Healthcare) or mouse IgG (NA931; GE Healthcare). Immunoreactive protein
bands were visualized using enhanced chemiluminescence (ECL Plus; GE Healthcare).
Immunofluorescence staining
SK-ES-1 cells, seeded on tissue culture chamber slides, were infected with OBP-301 (5 MOI)
for 48 h. Cells were irradiated at 1 Gy, and then 30 min, 1 h, or 3 h following irradiation, cells
were fixed with chilled 1% paraformaldehyde in phosphate-buffered saline (PBS) for 10 min
on ice. The slides were subsequently incubated with primary mouse anti-γH2AX mAb (05–
636; Millipore) for 24 h. After washing three times with PBS, slides were incubated with the
secondary FITC-conjugated antibody against mouse IgG (61–6511; Zymed Laboratories Inc.,
South San Francisco, CA, USA) for 30 min on ice. The slides were further stained with Pro-
Long1 Gold antifade reagent with DAPI (life technologies Co., Carlsbad, CA, USA) and then
analyzed under a confocal laser microscope (FV10i; Olympus Co., Tokyo, Japan).
In vivo subcutaneous human STS xenograft tumor models
Animal experimental protocols were approved by the Ethics Review Committee for Animal
Experimentation of Okayama University School of Medicine. The experiments were con-
ducted in accordance with the Policy on the Care and Use of the Laboratory Animals, Oka-
yama University. All mice were maintained under barrier conditions with sterile diet and
water. Under general anesthesia with 2% isoflurane, SK-ES-1 (5 × 106 cells/mouse) and
HT1080 (3 × 106 cells/mouse) cells were subcutaneously inoculated into the flanks of 5- to
6-week-old female BALB/c nu/nu mice (CLEA Japan, Tokyo, Japan). When tumors reached 5
to 7 mm in diameter, the mice were irradiated at a dosage of 1 Gy/tumor (SK-ES-1) or 3 Gy/
tumor (HT1080) every week for one or three cycles starting at day 0. During irradiation, mice
were placed in a prone position, using custom-made holders that contain lead collimators to
shield the upper half of the animal. A 50 μL solution containing OBP-301 at a dose of 1 × 108
PFU/tumor or PBS was injected into the tumors every week for one or three cycles. The per-
pendicular diameter of each tumor was measured every 3–4 days, and tumor volume was cal-
culated with the following formula: tumor volume (mm3) = a × b2 × 0.5, where a is the longest
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diameter, b is the shortest diameter, and 0.5 is a constant to calculate the volume of an ellip-
soid. Animals were monitored every 3–4 days and there were no severe signs of illness or
death due to the experimental procedures. When the mean tumor volume reached 4000 mm3,
mice were sacrificed by cervical dislocation after general anesthesia with 2% isoflurane.
Histopathologic analysis
Tumors were fixed in 10% neutralized formalin and embedded in paraffin blocks. Sections
were stained with hematoxylin/eosin. Sections were also prepared for immunohistochemical
examination using mouse anti-γH2AX mAb (05–636; Millipore) and rabbit anti-Ki67 mAb
(ab16667; Abcam, Cambridge, UK). Immunoreactive signals were visualized using 3,3’-diami-
nobenzidine (DAB) solution (Nichirei Bioscience, Tokyo, Japan), and nuclei were counter-
stained with hematoxylin. All sections were analyzed under a light microscopy.
TUNEL staining
Sections were deparaffinized and put into 3% hydrogen peroxide for 10 min at room tempera-
ture. After nonspecific binding sites were blocked, the sections were incubated for 60 min at
37˚C with terminal deoxynucleotidyltransferase mediated dUTP nick end labeling (TUNEL;
Roche Applied Science, Penzberg, Germany) and stained with DAB solution. Finally, all sec-
tions were counterstained with hematoxylin. Sections were rinsed with PBS after every step.
Statistical analysis
Data were expressed as mean ± SD. Differences between two groups were examined for statis-
tical significance with the Student’s t test. One-way ANOVA followed by a Games-Howell
multiple-group comparison test was used to compare differences between groups in animal
experiments. P values < 0.05 were considered statistically significant.
Results
In vitro radiosensitizing effect of OBP-301 in human STS cells
To evaluate the radiosensitizing effect of OBP-301 in STS cells, we first analyzed the baseline
sensitivity of four human STS cell lines (RD-ES, SK-ES-1, HT1080, and NMS-2) to ionizing
radiation. The viability of RD-ES and SK-ES-1 (Ewing sarcoma) cells when irradiated at 2 Gy
was decreased to approximately half that of non-irradiated cells, as measured by XTT assay
(Fig 1A). In contrast, the viability of HT1080 (fibrosarcoma) and NMS-2 (MPNST) was
reduced by less than 50% compared to the viability of non-irradiated cells, even up to 10 Gy
(Fig 1A). These results indicate that RD-ES and SK-ES-1 cells are highly radiosensitive,
whereas HT1080 and NMS-2 cells are moderately radiosensitive.
We next evaluated the combined effect of OBP-301 and ionizing radiation on viability. All
four STS cell lines were irradiated 24 h after OBP-301 infection, and cell viability was assessed
on day 4 after irradiation. The combination of OBP-301 and ionizing radiation decreased the
viability of all STS cell lines more efficiently than single treatment (Fig 1B). Calculation of the
combination index indicated a synergistic antitumor effect of combination therapy in all STS
cell lines, although in moderately radiosensitive NMS-2 cells there was an antagonistic effect
found with low doses of ionizing radiation and OBP-301 (Fig 1C). These results suggest that
OBP-301 may act as a potent radiosensitizer in human STS cells.
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Suppression of anti-apoptotic MCL1 is involved in enhancing ionizing
radiation-induced apoptosis by OBP-301
To investigate the underlying molecular mechanism in the OBP-301-mediated enhancement
of radiotherapy, we analyzed the level of anti-apoptotic MCL1 expression in all STS cells. Inter-
estingly, moderately radiosensitive HT1080 and NMS-2 cells exhibited high expression of
MCL1 protein, whereas highly radiosensitive RD-ES and SK-ES-1 cells showed low expression
of MCL1 protein (Fig 2A). These results suggest that the expression of MCL1 is associated
with the radiosensitivity of STS cells.
We recently reported that OBP-301 enhances the cytotoxic effect of chemotherapeutic
agents in human osteosarcoma cells by suppressing MCL1 expression through the activation
of a transcription factor E2F1-microRNA pathway, resulting in the induction of apoptosis
[17]. Therefore, we next assessed whether OBP-301 enhances ionizing radiation-induced apo-
ptosis by suppressing MCL1 expression in highly radiosensitive SK-ES-1 and moderately
Fig 1. In vitro radiosensitizing effect of OBP-301 on human soft tissue sarcoma cells. A, Four human soft tissue sarcoma (STS) cell lines (RD-ES, SK-ES-1,
HT1080, NMS-2) were irradiated at the indicated dose, and cell viability was assessed 4 days after irradiation using the XTT assay. RD-ES and SK-ES-1 cells are
highly radiosensitive, whereas HT1080 and NMS-2 cells are moderately radiosensitive. Data are expressed as mean ± SD of independent experiments (n = 5). B,
Cells were irradiated at the indicated doses 24 h after infection with OBP-301 at the indicated MOIs, and cell viability was assessed 4 days after irradiation. C, The
combination index was calculated using CalcuSyn software. Synergism and antagonism were defined as interaction indices of< 1 and> 1, respectively.
https://doi.org/10.1371/journal.pone.0250643.g001
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radiosensitive HT1080 cells. OBP-301 infection at high doses increased the expression of ade-
noviral E1A and E2F1, whereas MCL1 expression was decreased in SK-ES-1 and HT1080 cells
(Fig 2B). The combination of OBP-301 and ionizing radiation induced apoptosis (PARP cleav-
age) in SK-ES-1 and HT1080 cells, which was associated with the upregulation of E2F1 and
downregulation of MCL1 (Fig 2C). To further confirm the role of MCL1 suppression in radia-
tion-induced apoptosis, we assessed the effect of MCL1 knockdown by RNA interference.
MCL1 siRNA suppressed MCL1 expression and resulted in the enhancement of ionizing radi-
ation-induced apoptosis in SK-ES-1 and HT1080 cells compared to control siRNA (Fig 2D).
These results suggest that OBP-301 enhances ionizing radiation-mediated apoptosis induction
via MCL1 suppression.
Enhancement of ionizing radiation-induced DNA damage by OBP-301
Therefore, we next investigated whether OBP-301 infection enhances ionizing radiation-
induced accumulation of DNA damage by evaluating the expression of γH2AX in SK-ES-1
cells. Ionizing radiation, when combined with OBP-301 infection, increased γH2AX expres-
sion in SK-ES-1 cells 30 min after treatment. At 1 and 3 h after irradiation, the level of γH2AX
expression remained elevated in OBP-301-infected cells. In contrast, in non-infected cells,
Fig 2. MCL1 suppression is involved in the OBP-301-mediated enhancement of apoptosis induced by ionizing radiation. A, Cell lysates were analyzed by
Western blot for MCL1 expression. B, SK-ES-1 and HT1080 cells were infected with OBP-301 at the indicated MOIs for 72 h, and cell lysates were analyzed by
Western blot for E1A, E2F1, and MCL1. C, SK-ES-1 and HT1080 cells were treated with OBP-301 and then irradiated (IR) at the indicated doses 24 h after
infection, and cell lysates were subjected to Western blot for PARP, cleaved PARP (C-PARP), E1A, E2F1, and MCL1. D, SK-ES-1 and HT1080 cells were
transfected with 10 nM MCL1 siRNA or control siRNA for 48 h, and subsequently irradiated at the indicated doses. Cell lysates were analyzed by Western blot
for PARP, C-PARP, and MCL1. β-actin was assayed as a loading control.
https://doi.org/10.1371/journal.pone.0250643.g002
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ionizing radiation increased γH2AX expression at 1 h, but the level gradually decreased follow-
ing the repair of DNA damage (Fig 3A). To further evaluate the amount of DNA damage, we
analyzed immunofluorescence staining of γH2AX using SK-ES-1 cells. There was no signifi-
cant difference in the number of nuclear γH2AX foci between OBP-301-infected and non-
infected cells at 30 min and 1 h following irradiation. However, at 3 h after irradiation, the
number of nuclear γH2AX foci was significantly lower in non-infected cells compared to
OBP-301-infected cells (Fig 3B and 3C). These results suggest that OBP-301 prolongs the accu-
mulation of ionizing radiation-induced DNA damage.
Effect of combination therapy in subcutaneous STS tumor tissues
To confirm the radiosensitizing effect of OBP-301 in tumor tissues, we assessed the level of
Ki67-positive (proliferation marker), TUNEL-positive (apoptosis marker), and γH2AX-posi-
tive staining (DNA damage marker) in subcutaneous xenograft tumors grown from highly
radiosensitive SK-ES-1 and moderately radiosensitive HT1080 cells (Figs 4 and 5). Tumor-
bearing mice were irradiated at 1 Gy (SK-ES-1) or 3 Gy (HT1080) after treatment with an
Fig 3. Enhancement of ionizing radiation-induced DNA damage by OBP-301. A, SK-ES-1 cells were infected with OBP-301 (10 MOI) and then irradiated
at 1 Gy, 24 h after infection. Cells were harvested 0.5, 1, and 3 h after irradiation and analyzed by Western blot for γH2AX expression. B, SK-ES-1 cells were
infected with OBP-301 (5 MOI) and then irradiated at 1 Gy, 24 h after infection. Cells were stained for γH2AX at 0.5, 1, and 3 h after irradiation and analyzed
by confocal laser microscopy. C, The average number of γH2AX foci per cell. Data are expressed as mean ± SD of independent experiments (n = 5; �,
P< 0.05).
https://doi.org/10.1371/journal.pone.0250643.g003
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intratumoral injection of OBP-301 (1 × 108 PFU/tumor). Subsequent immunohistochemical
analysis demonstrated that the combination of OBP-301 and ionizing radiation significantly
decreased the percentage of Ki67-positive proliferating cells compared to mock or single treat-
ment in SK-ES-1 tumor tissues (Fig 4B and 4C). The number of TUNEL-positive cells was sig-
nificantly increased in combination therapy-treated SK-ES-1 tumors compared with mock or
monotherapy-treated tumors (Fig 4C). Moreover, combination therapy significantly increased
the number of γH2AX-positive cells within SK-ES-1 tumor tissues (Fig 4C). Immunohisto-
chemical analysis for moderately radiosensitive HT1080 tumors demonstrated similar find-
ings, in that the percentage of Ki-67-positive cells was significantly decreased, and the number
of TUNEL-positive and γH2AX-positive cells was significantly increased, in combination ther-
apy-treated tumor tissues (Fig 5). These results suggest that the biological interaction between
OBP-301 and ionizing radiation is induced in in vivo tumor tissues as well as in vitro.
Fig 4. Suppression of proliferation and induction of apoptosis and DNA damage in subcutaneous SK-ES-1 xenograft tumors treated with OBP-301
and ionizing radiation. A, Scheme of treatment protocol used in conjunction with Ki67, TUNEL, and γH2AX assays. SK-ES-1 cells (5 × 106 cells/mouse)
were subcutaneously inoculated into the right flanks of mice. Tumor-bearing mice were irradiated at 1 Gy after treatment with an intratumoral injection
of OBP-301 (1 × 108 PFU/tumor). B, SK-ES-1 subcutaneous tumor sections were immunostained for Ki67, TUNEL, and γH2AX. Scale bar, 50 μm. C, The
number of positive cells for Ki67, TUNEL, and γH2AX staining. Data are expressed as mean ± SD of independent experiments (n = 3 in each group; ��,
P< 0.01).
https://doi.org/10.1371/journal.pone.0250643.g004
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Combination of OBP-301 and ionizing radiation inhibits the in vivo
growth of STS tumors with different radiosensitivities
To assess the in vivo therapeutic efficacy of OBP-301 in combination with ionizing radiation,
we again used the subcutaneous xenograft models for highly radiosensitive SK-ES-1 (Fig 6A)
and moderately radiosensitive HT1080 cells (Fig 6B). Highly radiosensitive SK-ES-1 tumors
were injected with OBP-301 (1 × 108 PFU/tumor) or PBS, and subsequently irradiated at 1 Gy
every week for three cycles, with tumor growth observed for 28 days after the first treatment.
The combination of OBP-301 and ionizing radiation showed a more profound antitumor
effect in highly radiosensitive SK-ES-1 tumors compared with ionizing radiation alone (Fig
6A). Moderately radiosensitive HT1080 tumors were injected with OBP-301 (1 × 108 PFU/
tumor) or PBS, and subsequently irradiated at 3 Gy every week for three cycles. Consistent
Fig 5. Suppression of proliferation and induction of apoptosis and DNA damage in subcutaneous HT1080 xenograft tumors treated with OBP-301
and ionizing radiation. A, Scheme of treatment protocol used in conjunction with Ki67, TUNEL, and γH2AX assays. HT1080 cells (3 × 106 cells/mouse)
were subcutaneously inoculated into the right flanks of mice. Tumor-bearing mice were irradiated at 3 Gy after treatment with an intratumoral injection of
OBP-301 (1 × 108 PFU/tumor). B, HT1080 subcutaneous tumor sections were immunostained for Ki67, TUNEL, and γH2AX. Scale bar, 50 μm. C, The
number of positive cells for Ki67, TUNEL, and γH2AX. Data are expressed as mean ± SD of independent experiments (n = 3 in each group; �, P< 0.05; ��,
P< 0.01).
https://doi.org/10.1371/journal.pone.0250643.g005
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with the findings from highly radiosensitive SK-ES-1 tumors, the combination of OBP-301
and ionizing radiation resulted in significant suppression of tumor growth compared with ion-
izing radiation alone (Fig 6B). However, there was no significant difference between groups
treated with combination therapy and monotherapy with OBP-301 in these xenograft models
(Fig 6A and 6B). There was no significant difference in the mean body weight of mice between
the treatment groups (S7 Fig). These results suggest that combination therapy with OBP-301
and ionizing radiation efficiently inhibits the growth of STS tumors in vivo.
Discussion
The multidisciplinary approach to STS treatment involves surgery, radiotherapy, and chemo-
therapy. Although surgical resection and radiotherapy are the most frequent option for STS,
resistance to radiotherapy contributes to tumor recurrence, metastasis, and poor prognosis
[3,4]. Therefore, the enhancement of radiosensitivity is a critical aspect of improving clinical
outcomes for STS patients, including minimizing the risk of secondary cancer by reducing the
required dose of ionizing radiation. In this study, we demonstrated that combination therapy
with OBP-301 and ionizing radiation has a synergistic antitumor effect in both highly radio-
sensitive and moderately radiosensitive STS cells. The profound antitumor effect of combina-
tion therapy was mainly due to OBP-301-mediated enhancement of ionizing radiation-
induced apoptosis and DNA damage, via suppression of anti-apoptotic MCL1 expression. Sev-
eral reports have suggested that MCL1 suppression with siRNA or small molecule inhibitors
enhances sensitivity to ionizing radiation-induced apoptosis in human cancer cells, including
melanoma [22], non-small cell lung cancer [23], and pancreatic cancer [24]. Thus, the combi-
nation of OBP-301 and ionizing radiation appears to be a promising antitumor strategy for
improving the efficacy of radiotherapy in STS patients.
Fig 6. In vivo antitumor effect of combination therapy with OBP-301 and ionizing radiation in the highly radiosensitive SK-ES-
1 and moderately radiosensitive HT1080 xenograft tumor models. A and B, SK-ES-1 cells (5 × 106 cells/mouse) or HT1080 cells
(3 × 106 cells/mouse) were subcutaneously inoculated into the right flanks of mice. When tumors reached 5 to 7 mm in diameter,
tumor-bearing mice were irradiated at 1 Gy (SK-ES-1) or 3 Gy (HT1080) after treatment with an intratumoral injection of OBP-301
(1 × 108 PFU/tumor) for three cycles every week (arrows indicate each treatment administration). The mock treatment group was
sacrificed on day 21 in the SK-ES-1 and HT1080 tumor models, when tumor volumes reached approximately 4000 mm3. Tumor
growth is expressed as mean tumor volume ± SD of independent experiments (n = 4 to 5 in each group; �, P< 0.05; ��, P< 0.01).
https://doi.org/10.1371/journal.pone.0250643.g006
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Our results demonstrated that moderately radiosensitive STS cells (HT1080 and NMS-2)
have higher expression of MCL1 compared to highly radiosensitive STS cells (RD-ES and
SK-ES-1), and suggested a role for MCL1 in the radiosensitivity of STS. We further demon-
strated that MCL1 suppression by siRNA or OBP-301 enhanced ionizing radiation-induced
apoptosis in STS cells. Similarly, it has been shown that MCL1 suppression with siRNA or anti-
sense oligonucleotides enhances chemotherapy-induced apoptosis in human STS cells [25].
Thus, anti-apoptotic MCL1 may be a promising therapeutic target for improving sensitivity to
both radiotherapy and chemotherapy in STS. Although our data supports that MCL1 is a key
molecule involved in the radiosensitivity of STS, further experiments would be needed to con-
firm whether MCL1 suppression enhances radiation-induced apoptosis in STS cells.
Previous reports have suggested that oncolytic adenoviruses suppress MCL1 expression in
infected cells [26,27], and the mechanism has been linked to adenoviral E1A accumulation
[28]. Adenoviral E1A accumulation induces the activation of transcription factor E2F1 [29],
which can contribute to MCL1 suppression [30,31]. These findings suggest that E1A-mediated
E2F1 activation is critical for the downregulation of MCL1 expression by oncolytic adenovirus.
Recently, we revealed that OBP-301 suppresses MCL1 expression in human osteosarcoma cells
through E2F1-mediated upregulation of the MCL1-targeting non-coding microRNA miR-29
[17]. Recent reports have further suggested a role for miR-29 in improving the radiosensitivity
of human cancers, including nasopharyngeal cancer [32] and lung cancer [33], via suppression
of MCL1 expression. Ionizing radiation itself also suppresses MCL1 expression, by inducing
miR-193a expression, resulting in the induction of apoptosis [34]. Therefore, the activation of
an MCL1-targeting miRNA signaling pathway may be implicated in the combination therapy-
mediated MCL1 suppression that we have observed in the present study.
In the present study, OBP-301 significantly enhanced the level of γH2AX in irradiated
tumor cells both in vitro and in vivo, suggesting that OBP-301 has the potential to enhance ion-
izing radiation-induced DNA damage and thus the sensitivity to ionizing radiation. We previ-
ously reported that OBP-301 inhibits the DNA damage repair pathway via adenoviral E1B-
dependent degradation of the MRN complex, which consists of Mre11, Rad50, and NBS1 pro-
teins [15]. Indeed, an accumulation of recent evidence has suggested that oncolytic adenovirus
inhibits DNA damage repair pathways via direct interaction between adenoviral proteins and
DNA damage response-related factors [35]. On the other hand, previous work has demon-
strated that MCL1 is associated with γH2AX and NBS1 following chemotherapy-induced
DNA damage in mouse embryo fibroblasts [36]. Mattoo and colleagues have shown that
knockdown of MCL1 by siRNA in human cancer cells, including osteosarcoma, increases
γH2AX levels after irradiation via impairment of the homologous recombination pathway
[37]. Thus, adenoviral protein accumulation and MCL1 reduction may be cooperatively
involved in the OBP-301-mediated inhibition of DNA damage repair.
HT1080 tumors were radiosensitive as similar with SK-ES-1 tumors. These findings suggest
that HT1080 tumors are not suitable to mimic the radioresistant STS tumors. Resistance to
radiotherapy is thought to be associated with the existence of cancer stem-like cells [38]. The
dormancy of such cells is a critical factor for the radioresistance of tumors, because radiother-
apy targets proliferating cancer cells by inducing DNA damage-related cell cycle arrest. Several
reports have suggested that a CD133-positive subpopulation of radioresistant HT1080 cells
exhibit cancer stem-like characteristics [39,40]. CD133-positive subpopulations have similarly
been associated with the radioresistance of brain tumor [41], liver cancer [42], and lung cancer
[43]. We previously demonstrated that OBP-301 efficiently kills radioresistant CD133-positive
cells, as well as radiosensitive CD133-negative cells, in human gastric cancer [44]. Therefore,
HT1080 tumors derived from radioresistant CD133-positive cells may be more suitable model
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to investigate the therapeutic potential of combination therapy with OBP-301 and ionizing
radiation.
In conclusion, we have demonstrated that combination therapy with OBP-301 and ionizing
radiation exerts a synergistic antitumor effect in STS cells. OBP-301 promoted ionizing radia-
tion-induced apoptosis through suppression of anti-apoptotic MCL1 expression and enhance-
ment of DNA damage. Furthermore, combination therapy showed a more profound
antitumor effect compared to monotherapy in highly and moderately radiosensitive STS xeno-
graft tumors. Thus, combination therapy with OBP-301 and ionizing radiation offers a prom-
ising antitumor strategy to improve the clinical outcome of radiotherapy-treated STS patients.
Further clinical studies are warranted to investigate the tolerability and efficacy of this combi-
nation therapy for the treatment of STS patients.
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